ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Nuvectis Pharma Inc

Nuvectis Pharma Inc (NVCT)

4.87
0.11
(2.31%)
Closed December 07 4:00PM
4.92
0.05
(1.03%)
After Hours: 7:59PM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
4.87
Bid
4.87
Ask
5.23
Volume
45,635
4.68 Day's Range 5.0097
4.60 52 Week Range 12.10
Market Cap
Previous Close
4.76
Open
4.82
Last Trade
25
@
4.87
Last Trade Time
Financial Volume
$ 219,888
VWAP
4.8184
Average Volume (3m)
177,933
Shares Outstanding
19,320,973
Dividend Yield
-
PE Ratio
-4.27
Earnings Per Share (EPS)
-1.15
Revenue
-
Net Profit
-22.26M

About Nuvectis Pharma Inc

Nuvectis Pharma Inc is a biopharmaceutical company. Nuvectis Pharma Inc is a biopharmaceutical company.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
-
Nuvectis Pharma Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker NVCT. The last closing price for Nuvectis Pharma was $4.76. Over the last year, Nuvectis Pharma shares have traded in a share price range of $ 4.60 to $ 12.10.

Nuvectis Pharma currently has 19,320,973 shares outstanding. The market capitalization of Nuvectis Pharma is $91.97 million. Nuvectis Pharma has a price to earnings ratio (PE ratio) of -4.27.

NVCT Latest News

PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update

Nuvectis Pharma (NASDAQ: NVCT) continues to make strides in precision oncology, gaining momentum following presentations last week at the AACR-NCI-EORTC Symposium where its drug candidate NXP900...

PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch

With its focus on targeting well-defined subgroups by inhibiting SRC/YES1 kinases in Non Small-Cell Lung Cancer patients resistant to EGFR and ALK targeted therapies, Nuvectis Pharmaโ€™s NXP900...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.39-7.41444866925.265.3654.6835364.87109433CS
4-3.5629-42.24999703548.432911.84.62718356.72672612CS
12-1.7-25.87519025886.5711.84.61779337.00571584CS
26-1.19-19.63696369646.0611.84.61322226.87281584CS
52-3.71-43.24009324018.5812.14.61132517.32851975CS
1560.9223.29113924053.9520.923.081915707.85511105CS
2600.9223.29113924053.9520.923.081915707.85511105CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
UPCUniverse Pharmaceuticals Inc
$ 3.38
(221.90%)
93.72M
LIFWMSP Recovery Inc
$ 3.2461
(104.16%)
29.08M
GXAIGaxos ai Inc
$ 2.5801
(81.70%)
146.21M
SBETSharpLink Gaming Inc
$ 0.9116
(73.97%)
27.09M
HCTIHealthcare Triangle Inc
$ 1.165
(68.38%)
4.34M
ORISOriental Rise Holdings Ltd
$ 3.6833
(-93.42%)
27.51M
LICNLichen China Limited
$ 0.4895
(-76.91%)
185.96M
MYNAMynaric AG
$ 0.499246
(-64.59%)
3.6M
CEROCERo Therapeutics Holdings Inc
$ 0.1146
(-40.16%)
37.87M
BTCTBTC Digital Ltd
$ 10.50
(-32.95%)
3.26M
SMXSMX Security Matters Public Company
$ 0.4879
(64.06%)
440.04M
SOUNSoundHound AI Inc
$ 15.01
(12.60%)
215.93M
LICNLichen China Limited
$ 0.4895
(-76.91%)
185.96M
NVDANVIDIA Corporation
$ 142.44
(-1.81%)
185.41M
SVMHSRIVARU Holding Ltd
$ 0.0293
(-16.29%)
160.45M

NVCT Discussion

View Posts
gail gail 3 weeks ago
grabbed some on the dip
๐Ÿ‘๏ธ0
Monksdream Monksdream 3 months ago
NVCT under $10
๐Ÿ‘๏ธ0
Monksdream Monksdream 5 months ago
NVCT under $10
๐Ÿ‘๏ธ0
Monksdream Monksdream 7 months ago
NVCT under $10
๐Ÿ‘๏ธ0
Monksdream Monksdream 9 months ago
NVCT 10Q due March 6
๐Ÿ‘๏ธ0
Monksdream Monksdream 11 months ago
NVCT a bounce
๐Ÿ‘๏ธ0
conix conix 3 years ago
NVCT HIGHLIGHTS:

*Recently completed Initial Public Offering - $5.00 Per share
*2 Precision Cancer medicines in development - ovarian and triple negative breast
*Data flow throughout 2022
*CEO with multiple success stories in life science sector to $billion dollar market caps
*Analysts project a $66 billion precision medicines market for 2021; In 6 years, this number is expected to top $140 billion

Nuvectis Pharma Inc - Company Background:

Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for serious conditions of unmet medical need in oncology. The Company is currently developing two drug candidates: NXP800, a clinical-stage HSF1 pathway inhibitor currently in a Phase 1 study in patients with advanced solid tumors, and NXP900, a novel SRC/YES1 kinase inhibitor currently in preclinical development with IND-enabling studies ongoing.

Market Capitalization: $225 million
Range - 52 week: $3.08 - $20.75
Current Price: $20.44
Trades on: Nasdaq Capital Market
Ticker Symbol: NVCT

website: nuvectis.com
๐Ÿ‘๏ธ0
TheFinalCD TheFinalCD 3 years ago
wow from $3 to almost $21
๐Ÿ‘๏ธ0
ipo_dude ipo_dude 3 years ago
$27 we come
๐Ÿ‘๏ธ0
TheFinalCD TheFinalCD 3 years ago
WOW $7 MOVE 3-10


CONGRAT$ NVCT
๐Ÿ‘๏ธ0
spindog spindog 3 years ago
I feel the same
๐Ÿ‘๏ธ0
kkballa kkballa 3 years ago
hmmm.
๐Ÿ‘๏ธ0

Your Recent History

Delayed Upgrade Clock